Bacillus calmette-guerin substrain tice live antigen

DB10343ApprovedInvestigationalVaccinesLive Attenuated Bacillus Calmette-Guerin ImmunotherapyLive Attenuated Bacillus Calmette-Guerin Vaccine

Bacillus calmette-guerin substrain tice live antigen is a live attenuated vaccine against Mycobacterium bovis. It is administered to prevent the development of tuberculosis.

First approval
Canada, 2011 · United States, 1989
Also known as
BCG, Live, Tice Strain
Brand names
  • BCG Vaccine
  • Tice Bcg

Resolves to

Compound
UNII2XQ558L16Z
Clinical / RWD
RxNorm221050

What you can answer from here — as of May 03, 2025

435Drug interactionsStructured to mechanism, not free text
Sign in
19Clinical trialsPhase, status and sponsor resolved per trial
Sign in
5Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
5Marketed productsAcross 4 countries and 3 labellers
Sign in

Which other approved drugs treat the same conditions as Bacillus calmette-guerin substrain tice live antigen, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In